Taking linagliptin in addition to basal insulin was more effective than a placebo and insulin combination in controlling blood sugar levels in patients with type 2 diabetes, according to a study in Diabetes Care. Sixteen percent of patients who took linagliptin attained an A1C of less than 7% after 52 weeks, compared with 7% in the placebo group.

Full Story:

Related Summaries